Our product candidate, PHX1766, is a protease inhibitor currently in preclinical development for the treatment of hepatitis C virus, or HCV, infection. [READ MORE]
May 16, 2008 - Phenomix Announces PHX1149 Phase 2B Clinical Trial Results For Type 2 Diabetes [READ MORE]